{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:46:18Z","timestamp":1791729978241,"version":"4.3.4"},"reference-count":37,"publisher":"SAABRON PRESS","issue":"2","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Chimeric antigen receptor T-cell therapy (CAR-T) has altered the treatment landscape of several hematologic malignancies. Until recently, most CAR-T infusions have been administered in the inpatient setting, due to their toxicity profile. However, the advent of new product constructs, as well as improved detection and management of adverse effects, have greatly increased the safety in administering these therapies. CAR-T indications continue to expand, and inpatient administration is associated with increased healthcare resource utilization and overall cost. Therefore, transitioning CAR-T administration to the outpatient setting has been of great interest in an effort to improve access, reduce financial burden, and improve patient satisfaction. Establishment of a successful outpatient CAR-T requires several components, including a multidisciplinary cellular therapy team and an outpatient center with appropriate clinical space and personnel. Additionally, clear criteria for outpatient administration eligibility and for inpatient admission with pathways for prompt toxicity evaluation and admission, and toxicity management guidelines should be implemented. Education about CAR-T therapy and its associated toxicities is imperative for all clinical staff, as well as patients and their caregivers. Finally, rigorous financial planning and close collaboration with payers to ensure equitable access, while effectively managing cost, are essential to program success and sustainability. This review provides a summary of currently published experiences, as well as expert opinion regarding implementation of an outpatient CAR-T program.<\/jats:p>","DOI":"10.46989\/001c.115793","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T01:14:56Z","timestamp":1712625296000},"source":"Crossref","is-referenced-by-count":25,"title":["Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations"],"prefix":"10.46989","volume":"6","author":[{"given":"Katie","family":"Gatwood","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00cj35179","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Kansas Cancer Center","department":["Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittney","family":"Baer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Pak","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City Of Hope National Medical Center","department":["Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lee","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01z1vct10","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoim","family":"Kim","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City Of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Abernathy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03cp5cj42","id-type":"ROR","asserted-by":"publisher"}],"name":"Sarah Cannon Research Institute","department":["Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["Medicine Hematology Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan","family":"Oluwole","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center","department":["MedicineHematology and oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"issue":"10299","key":"ref1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Bijal D Shah","year":"2021","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"14","key":"ref2","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/nejmoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Michael Wang","year":"2020","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"4","key":"ref3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/nejmoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Jes\u00fas San-Miguel","year":"2023","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref4","article-title":"Tisagenlecleucel (Kymriah) [prescribing information]","author":"NP Corp","year":"2022"},{"key":"ref5","article-title":"Lisocabtagene maraleucel (Breyanzi) [prescribing information]","author":"Juno Therapeutics","year":"2022"},{"key":"ref6","article-title":"Axicabtagene autoleucel (Yescarta) [prescribing information]","author":"Kite Pharma I","year":"2022"},{"key":"ref7","article-title":"Brexucabtagene autoleucel (Tecartus) [prescribing information]","author":"Kite Pharma I","year":"2021"},{"key":"ref8","article-title":"Ciltacabtagene autoleucel (Carvykti) [prescribing information]","author":"Janssen Biotech I","year":"2023"},{"key":"ref9","article-title":"Idecabtagene vicleucel (Abecma) [prescribing information]","author":"Celgene Corp. aB-MSC","year":"2021"},{"issue":"16_suppl","key":"ref10","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1200\/jco.2023.41.16_suppl.1533","article-title":"Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma.","volume":"41","author":"Radhika Bansal","year":"2023","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"10254","key":"ref11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Jeremy S Abramson","year":"2020","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"6","key":"ref12","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41409-022-01664-z","article-title":"Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center","volume":"57","author":"Azra Borogovac","year":"2022","journal-title":"Bone Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"6","key":"ref13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/bjh.18339","article-title":"Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience","volume":"198","author":"Bhagirathbhai Dholaria","year":"2022","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"Supplement 1","key":"ref14","doi-asserted-by":"publisher","first-page":"10416","DOI":"10.1182\/blood-2022-159595","article-title":"Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community\/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL)","volume":"140","author":"Yuliya Linhares","year":"2022","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"8","key":"ref15","doi-asserted-by":"publisher","first-page":"e730","DOI":"10.1016\/j.clml.2022.04.012","article-title":"Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting","volume":"22","author":"Sunita D. Nasta","year":"2022","journal-title":"Clinical Lymphoma Myeloma and Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/2152-2650","issn-type":"print"},{"issue":"7","key":"ref16","doi-asserted-by":"publisher","first-page":"449.e1","DOI":"10.1016\/j.jtct.2023.04.019","article-title":"Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma","volume":"29","author":"Nausheen Ahmed","year":"2023","journal-title":"Transplantation and Cellular Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/2666-6367","issn-type":"print"},{"issue":"4","key":"ref17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/bjh.19090","article-title":"Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages","volume":"203","author":"Andrew Ly","year":"2023","journal-title":"British journal of haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"9","key":"ref18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jtct.2022.06.021","article-title":"Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy","volume":"28","author":"Mary McGann","year":"2022","journal-title":"Transplantation and Cellular Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/2666-6367","issn-type":"print"},{"issue":"7","key":"ref19","doi-asserted-by":"publisher","first-page":"429.e1","DOI":"10.1016\/j.jtct.2023.03.019","article-title":"Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma","volume":"29","author":"Chiara De Philippis","year":"2023","journal-title":"Transplantation and Cellular Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/2666-6367","issn-type":"print"},{"issue":"20","key":"ref20","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","article-title":"How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy","volume":"141","author":"Michael D. Jain","year":"2023","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"4","key":"ref21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Olalekan O. Oluwole","year":"2021","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"10297","key":"ref22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Jesus G Berdeja","year":"2021","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"4","key":"ref23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.6004\/jadpro.2019.10.4.12","article-title":"Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy","volume":"10","author":"Alix Beaupierre","year":"2019","journal-title":"Journal of the Advanced Practitioner in Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/2150-0878","issn-type":"print"},{"issue":"S1","key":"ref24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jha2.333","article-title":"Chimeric antigen receptor T-cell therapy: Challenges and framework of outpatient administration","volume":"3","author":"Katie S. Gatwood","year":"2021","journal-title":"eJHaem","ISSN":"https:\/\/id.crossref.org\/issn\/2688-6146","issn-type":"print"},{"issue":"7","key":"ref25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jtct.2021.01.014","article-title":"Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration","volume":"27","author":"Maurice Alexander","year":"2021","journal-title":"Transplantation and Cellular Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/2666-6367","issn-type":"print"},{"issue":"4","key":"ref26","doi-asserted-by":"publisher","first-page":"e002056","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"G Doug Myers","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/2051-1426","issn-type":"print"},{"key":"ref27","article-title":"CAR-T Therapy Coding and Billing Guide","author":"Therapy ASfTaC","year":"2023"},{"key":"ref28","article-title":"CAR-T Reimbursement Updated in FY 2024 IPPS Final Rule","author":"G. Kolton","year":"2023","journal-title":"Avalere"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd011865.pub2","article-title":"Payment methods for healthcare providers working in outpatient healthcare settings","volume":"1","author":"Liying Jia","year":"2021","journal-title":"Cochrane Database of Systematic Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/1465-1858","issn-type":"print"},{"issue":"14","key":"ref30","doi-asserted-by":"publisher","first-page":"11803","DOI":"10.3390\/ijms241411803","article-title":"CAR-T State of the Art and Future Challenges, A Regulatory Perspective","volume":"24","author":"Lorenzo Giorgioni","year":"2023","journal-title":"International Journal of Molecular Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/1422-0067","issn-type":"print"},{"issue":"10343","key":"ref31","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/s0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Manali Kamdar","year":"2022","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"7","key":"ref32","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/nejmoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Frederick L. Locke","year":"2022","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"8","key":"ref33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/nejmoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Nikhil C. Munshi","year":"2021","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"19","key":"ref34","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2022018893","article-title":"5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)","volume":"141","author":"Sattva S. Neelapu","year":"2023","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"26","key":"ref35","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Sattva S. Neelapu","year":"2017","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"1","key":"ref36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Stephen J. Schuster","year":"2019","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"8","key":"ref37","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/s1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Alison Sehgal","year":"2022","journal-title":"The Lancet Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/1470-2045","issn-type":"print"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/115793-outpatient-car-t-cell-therapy-as-standard-of-care-current-perspectives-and-considerations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:49:53Z","timestamp":1791726593000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/115793-outpatient-car-t-cell-therapy-as-standard-of-care-current-perspectives-and-considerations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.115793","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}